Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.66 |
| ▸ | HTR2B | P41595 | 2/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153136 | 0.87 | HTR2A (0.60) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| SCHEMBL18893217 | 0.83 | HTR2A (0.64) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL30081489 | 0.80 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL30081494 | 0.80 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL29390405 | 0.80 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL895637 | 0.80 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL44927 | 0.80 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL4668266 | 0.80 | HTR2A (1.00) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL8412627 | 0.78 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1LMNA | |
| Nordexfenfluramine SCHEMBL10562287 | 0.78 | HTR2A (0.96) | HTR2AHTR2BHTR2CSIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | HTR2A 192/4885HTR2B 311/4885HTR2C 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.